MARKET

TOCA

TOCA

Tocagen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6031
+0.0387
+6.86%
After Hours: 0.6170 +0.0139 +2.30% 17:41 01/17 EST
OPEN
0.5700
PREV CLOSE
0.5644
HIGH
0.6300
LOW
0.5595
VOLUME
710.51K
TURNOVER
--
52 WEEK HIGH
12.00
52 WEEK LOW
0.4220
MARKET CAP
14.41M
P/E (TTM)
-0.1881
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of TOCA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

TOCA News

  • Introducing Tocagen (NASDAQ:TOCA), The Stock That Tanked 94%
  • Simply Wall St..3d ago
  • Is Tocagen Inc. (TOCA) A Good Stock To Buy?
  • Insider Monkey.12/23/2019 19:55
  • The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic
  • Benzinga.12/19/2019 12:52
  • The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data
  • Benzinga.12/18/2019 12:23

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About TOCA

Tocagen Inc. (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells. Its lead product candidates are vocimagene amiretrorepvec (Toca 511) and flucytosine extended release (Toca FC). Toca 511 is an investigational injectable retroviral replicating vector (RRV) that encodes a prodrug activator enzyme, cytosine deaminase (CD). Toca FC is an investigational extended-release version of 5-fluorocytosine (5-FC), a prodrug that is inactive as an anti-cancer drug. As of February, 2017, Tocagen has completed enrollment of the Phase II portion with 187 patients.
More

Webull offers Tocagen Inc (TOCA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.